Itacitinib

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Graft-versus-host-disease

Conditions

Chronic Graft-versus-host-disease

Trial Timeline

Jun 5, 2020 → Sep 7, 2023

NCT ID

NCT04200365

About Itacitinib

Itacitinib is a phase 2 stage product being developed by Incyte for Chronic Graft-versus-host-disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04200365. Target conditions include Chronic Graft-versus-host-disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05561985	Pre-clinical	Active	—	—	STAT1 Gain-of-Function Disease
NCT05823571	Phase 1	Active	Jul 6, 2023	Mar 1, 2030	Leukemia, Acute
NCT05063110	Phase 2	Completed	May 3, 2022	Oct 1, 2025	Adults Patients Having Non Severe HLH
NCT04629508	Phase 2	Completed	Jul 12, 2021	Aug 24, 2023	Myelofibrosis
NCT04640025	Phase 2	Active	Mar 10, 2021	Jun 22, 2026	Myelofibrosis
NCT04446182	Phase 2	Terminated	Jan 29, 2021	Jan 30, 2023	Chronic Graft-versus-host-disease
NCT04200365	Phase 2	Terminated	Jun 5, 2020	Sep 7, 2023	Chronic Graft-versus-host-disease
NCT03978637	Phase 1/2	Terminated	Feb 4, 2020	Oct 13, 2023	Bronchiolitis Obliterans Syndrome
NCT03670069	Phase 1	Terminated	Sep 30, 2019	May 6, 2024	Metastatic Leiomyosarcoma
NCT03755414	Phase 1	Completed	Sep 4, 2019	May 26, 2024	Acute Myelogenous Leukemia
NCT01633372	Phase 2	Completed	Jul 16, 2012	Jun 29, 2021	MPN (Myeloproliferative Neoplasms)

Competing Products

20 competing products in Chronic Graft-versus-host-disease

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Incyte

ruxolitinib creamApproved

Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3

Povorcitinib + PlaceboPhase 3

Ruxolitinib Cream + Vehicle CreamPhase 3

Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3